News | June 30, 2022
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
The settlement and dismissal resolves all claims between the parties
The settlement and dismissal resolves all claims between the parties
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated
